PF4 Stock Chart & Stats
€1.33
-€0.01(-0.75%)
At close: 4:00 PM EDT
€1.33
-€0.01(-0.75%)
Day’s Range― - ―
52-Week Range€3.65 - €8.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)20.00
Market Cap
€31.11M
Enterprise Value€43.46
Total Cash (Recent Filing)€2.69M
Total Debt (Recent Filing)€974.00K
Price to Earnings (P/E)<0.1
Beta-0.22
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)26.91
Shares Outstanding5,540,181
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe move from substantial historical losses to sustained profitability through 2023–2025 and TTM indicates a meaningful improvement in operating performance. If maintained, positive operating income and strong gross profit can support reinvestment, resilience, and better internal funding over the next several quarters.
Balance Sheet StrengthPositive equity combined with very low debt gives the company greater financial flexibility than in its earlier deficit periods. Minimal leverage reduces balance-sheet pressure and may allow management to preserve cash, fund operations, and respond to changing diagnostic-market conditions without heavy financing obligations.
Positive Cash GenerationPositive operating and free cash flow provide direct support for the company’s operations and reduce reliance on external capital. Free cash flow close to reported net income is also a favorable earnings-quality signal, suggesting recent profitability has translated into meaningful cash generation.
Bears Say
Declining RevenueShrinking revenue is a durable concern because it can weaken operating scale, reduce the base supporting fixed laboratory costs, and limit future earnings growth. Continued top-line contraction may also make the recent profitability improvement harder to sustain across the next several reporting periods.
Weakening Cash ConversionAlthough cash flow remains positive, weaker TTM conversion means earnings are growing faster than operating cash generation. That divergence can reduce financial flexibility and makes the current earnings profile less durable, particularly if the weaker cash-flow trend persists while revenue continues to decline.
Earnings Quality UncertaintyAn unusually high net margin alongside a history of sharp equity and return swings makes the current profit run-rate less predictable. If non-core or one-time influences contributed materially, reported earnings may overstate recurring business performance and provide a less reliable base for future results.
PF4 FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was €3.65 and its highest was €8.60 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is €31.11M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is Nov 11, 2026 which is in 53 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Currently, no data Available
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 5,540,181 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in DE:PF4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.